Skip to main content

TECHNOLOGY AND CODE article

Front. Immunol.

Sec. Antigen Presenting Cell Biology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1525576

Predicting Reverse-Bound Peptide Conformations in MHC Class II with PANDORA

Provisionally accepted
Daniel Rademaker Daniel Rademaker 1,2Farzaneh Parizi Farzaneh Parizi 2Marieke van Vreeswijk Marieke van Vreeswijk 2Sanna Eerden Sanna Eerden 2Dario Francesco Marzella Dario Francesco Marzella 2Li Xue Li Xue 2*
  • 1 University of Amsterdam, Amsterdam, Netherlands
  • 2 Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, Netherlands

The final, formatted version of the article will be published soon.

    Recent discoveries have transformed our understanding of peptide binding in Major Histocompatibility Complex (MHC) molecules, showing that peptides, for some MHC class II alleles, can bind in a reverse orientation (C-terminus to N-terminus) and can still effectively activate CD4+ T cells. These finding challenges established concepts of immune recognition and suggests new pathways for therapeutic intervention, such as vaccine design. We present an updated version of PANDORA, which, to the best of our knowledge, is the first tool capable of modeling reversed-bound peptides. Modeling these peptides presents a unique challenge due to the limited structural data available for these orientations in existing databases. PANDORA has overcome this challenge through integrative modeling using algorithmically reversed peptides as templates. We have validated the new PANDORA feature through two targeted experiments, achieving an average backbone binding-core L-RMSD value of 0.63 Å. Notably, it maintained low RMSD values even when using templates from different alleles and peptide sequences. Our results suggest that PANDORA will be an invaluable resource for the immunology community, aiding in the development of targeted immunotherapies and vaccine design.

    Keywords: Reverse-Bound Peptides, HLA II, Homology Modeling, Peptide-MHC, MHC II

    Received: 09 Nov 2024; Accepted: 24 Feb 2025.

    Copyright: © 2025 Rademaker, Parizi, van Vreeswijk, Eerden, Marzella and Xue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Li Xue, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, 6525 GA, Netherlands

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more